NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BiVACOR

BiVACOR

Private
Huntington Beach, CaliforniaHealthcare & Life Scienceshttps://bivacor.com/

Last Round

Grant

Feb 20, 2024

Total Funding Raised

$39.58M

Company Overview

BiVACOR is a medical device company developing a total artificial heart to provide a long-term solution for patients with end-stage biventricular heart failure.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

total artificial heartTAHartificial heartmechanical circulatory supportMCSimplantable heart pumpbridge-to-transplantBTTmagnetically levitated pumpheart failure treatmentcardiovascular medical devicedestination therapymechanical heartFDA Breakthrough Devicebionic heart

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BiVACOR Comparables

Compare BiVACOR with similar companies based on industry and business-model similarity.

BiVACOR comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Carmat
85%
Picard Medical, Inc.
83%
Neocor Therapeutics
82%

BiVACOR Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 20, 2024
VC RoundMar 29, 2023
Series BMay 19, 2021
GrantMay 19, 2021
Series AMay 17, 2018
Grant
Oct 25, 2017

Key People

Founding team and executive leadership

Daniel Timms

Founder CTO

Founding Team

BiVACOR Investors

Notable investors and investment history

BiVACOR investors
InvestorRounds
OneVenturesSeries B, Series A, VC Round
NIH RADxGrant
Queensland GovernmentGrant
Monash UniversityGrant
National Heart, Lung, and Blood InstituteGrant
Cormorant Asset ManagementSeries B, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 7, 2025

    Grew 16% QoQ, from 45 to 52 employees.

  • Feb 20, 2024

    Secured $13M from Medical Research Future Fund and Monash University.

BiVACOR Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BiVACOR Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BiVACOR's valuation, stock price, and market status.

Firmographic Details

HeadquartersHuntington Beach, California
Employee Range75
Year Founded2008
Last FundingFeb 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.